Virologists from the KU Leuven Rega Institute in Belgium get proven that a treatment with the anti-malaria drug hydroxychloroquine doesn’t restrict SARS-CoV-2 coronavirus replication in hamsters. A excessive dose of the anti-flu drug favipiravir, by inequity, has an antiviral fabricate in the hamsters. The team printed their findings in the Court docket cases of the National Academy of Sciences (PNAS).
To take a look at the efficacy of the vaccine and antivirals preclinically, the researchers consume hamsters. The rodents are severely upright for SARS-CoV-2 compare for the reason that virus replicates itself strongly in hamsters after an infection. Moreover, hamsters fabricate a lung pathology equivalent to soft COVID-19 in humans. This is now not the case with mice, as an instance.